会社概要
- 正式社名: Hybio Pharmaceutical Co.,Ltd
- 登録国: China
- 住所: Hybio Innovation Industry Building, , No. 7, Guansheng 4th Rd, , Guanlan High-tech Park,, Shenzhen
- 従業員数: 500 - 999
説明:
Founded in 1998, Hybio is a high-tech enterprise specializing in R&D and manufacturing of diverse peptide products, growing into a leading peptide pharmaceutical company and the first of its kind to go public in China (2011, stock code 300199). The company offers a full range of peptide products (API and finished dosage forms) and services (CRO and CDMO), with peptide finished products mainly sold domestically and peptide APIs supplied worldwide, and its Shenzhen headquarters has passed local and national NMPA GMP inspections more than 90 times.
事業活動
原薬(API)
製造業者原薬メーカー
完成医薬品(製剤)
製造業者原薬メーカー
先発品原薬
製造業者原薬メーカー
販売市場
- East Asia: China, Democratic People's Republic of Korea, Mongolia, Republic of Korea, Japan, Taiwan
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Melanesia: Papua New Guinea
- Western Asia: United Arab Emirates, Armenia, Azerbaijan
主要製品/サービス
当社の製品・サービス
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
認証
FDA
GMP
証明
CPHI Americas 2026
06/2026 – 06/2026
CPHI Americas 2026
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す